Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Novel analgesic agents imparted in recent patent literature

Dec. 18, 2008

BioDelivery Sciences resubmits NDA for Onsolis to FDA

Dec. 18, 2008

Phase IIa clinical trial results of LX-6171 in AAMI lead to reevaluation of future development

Dec. 18, 2008

FDA issues complete response letter denying approval to Pain's NDA for Remoxy

Dec. 18, 2008

FDA approves Athersys' IND to initiate phase I clinical trial of MultiStem in ischemic stroke

Dec. 18, 2008

Recent patents describe novel agents for neuropsychiatric disorders

Dec. 17, 2008

LCT reports results from preclinical rat studies of NeurotrophinCell in PD

Dec. 17, 2008

Synosia initiates proof-of-concept trial of nitisinone in RLS

Dec. 17, 2008

Impax discusses phase III IPX-056 trial results with FDA

Dec. 17, 2008

First phase III results released for FTY-720, a novel oral therapy for MS

Dec. 17, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
CINP 2026: Gut microbiota could predict antidepressant response
BioWorld
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
Ascending BCI systems deepen national security, ethical concerns
BioWorld
Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...